Ibandronate: Is there an effect on nonvertebral fractures?

Clinical Rheumatology

Volumn 27, Issue 10, 2008, Pages 1313-1315

  Kastelan, Darko ^a   Korsic, Mirko ^a   Vlak, Tonko ^b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Adherence; Fractures; Ibandronate; Nonvertebral; Osteoporosis; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO;

ARTICLE; CLINICAL DECISION MAKING; CLINICAL TRIAL; DATA ANALYSIS; EVIDENCE BASED MEDICINE; FRACTURE; HIGH RISK PATIENT; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION;

BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; META-ANALYSIS AS TOPIC; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 51549118444     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0971-4     Document Type: Article

References (15)

1. Recker RR, Gallagher R, Amonkar M et al (2004) Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res 19(Suppl 1):SA407
2. Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903
3. Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310
4. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
5. Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661
6. Stakkestad JA, Lakatos P, Lorenc R et al (2008) Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long term extension. Clin Rheumatol 27(8):955-960
7. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245
8. Cranney A, Wells G, Adachi R (2007) Non-vertebral fracture reduction with high-versus low-dose ibandronate: A meta-analysis of individual patient data. Ann Rheum Dis 66(Suppl II):681
9. Cortet B, Benichou O (2006) Adherence, persistence, concordance: Do we provide optimal management to our patients with osteoporosis? Joint Bone Spine 73:e1-7
10. Grazio S, Babic-Naglic D, Kehler T et al (2008) Persistence of weekly alendronate: A real-world study in Croatia. Clin Rheumatol 27:651-653
11. Cooper A, Drake J, Brankin E, the PERSIST Investigators (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: Results from the PERSIST study. Int J Clin Pract 60:896-905
12. Silverman SL, Chesnut CH, Amonkar MM et al (2006) Improved persistence in women with postmenopausal osteoporosis treated with once-monthly ibandronate versus weekly bisphosphonates: A first look. J Bone Miner Res 21(Suppl 1):SU335
13. Mc Combs JS, Thiebaud P, Mc Laughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
14. Caro JC, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
15. Cotte FE, Cortet B, Lafuma A et al (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75:201-208